Display options
Cite
La Salvia A, Sesti F, Grinzato C, et al. Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review. Pharmaceuticals (Basel). 2021;14(10)doi: 10.3390/ph14101039.
La Salvia, A., Sesti, F., Grinzato, C., Mazzilli, R., Tarsitano, M. G., Giannetta, E., & Faggiano, A. (2021). Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review. Pharmaceuticals (Basel, Switzerland), 14(10), . https://doi.org/10.3390/ph14101039
La Salvia, Anna, et al. "Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review." Pharmaceuticals (Basel, Switzerland) vol. 14,10 (2021). doi: https://doi.org/10.3390/ph14101039
La Salvia A, Sesti F, Grinzato C, Mazzilli R, Tarsitano MG, Giannetta E, Faggiano A. Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review. Pharmaceuticals (Basel). 2021 Oct 12;14(10). doi: 10.3390/ph14101039. PMID: 34681263; PMCID: PMC8538402.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2021 Oct 12;14(10). doi: 10.3390/ph14101039.

Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review.

Pharmaceuticals (Basel, Switzerland)

Anna La Salvia, Franz Sesti, Chiara Grinzato, Rossella Mazzilli, Maria Grazia Tarsitano, Elisa Giannetta, Antongiulio Faggiano

Affiliations

  1. Department of Oncology, 12 de Octubre University Hospital, 28045 Madrid, Spain.
  2. Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
  3. Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy.

PMID: 34681263 PMCID: PMC8538402 DOI: 10.3390/ph14101039

Abstract

Neuroendocrine neoplasms (NENs) are relatively rare and complex tumors that can be sporadic or hereditary, as in the context of multiple endocrine neoplasia type 1 (MEN1) where patients display a 70% lifelong risk of developing a pancreatic NENs (pNENs). To date, specific personalized treatment for pNENs in patients with MEN1 are lacking. The aim of this study was to systematically analyze the efficacy and safety of somatostatin analogue (SSA) treatment in patients affected by MEN1-related pNENs. We performed a systematic review of the literature, searching for peer-reviewed articles on SSA (octreotide or lanreotide) treatment in MEN1 associated with pNENs. We selected 20 studies with a pooled population of 105 MEN1 patients with pNENs. Females were 58.5%, median age was 44 years (18-73). TNM stage at diagnosis was stage I-II in 84.8% and stage IV in 15.2%. The overall response rate (SD+PR+CR) was achieved in 88.3% of cases, with stable disease in 75.6% and objective response in 12.7% of patients. The safety profile was favorable with both SSA agents. SSAs appear to be an effective and safe treatment option for MEN1-related pNEN, either at localized or advanced stages.

Keywords: MEN-1; efficacy; pancreatic neuroendocrine tumors; personalized treatment; safety; somatostatin analogues

References

  1. J Oncol Pharm Pract. 2019 Sep;25(6):1425-1433 - PubMed
  2. Endocrine. 2014 Aug;46(3):678-81 - PubMed
  3. Cell Mol Gastroenterol Hepatol. 2015 Jan 12;1(2):131-153 - PubMed
  4. Invest New Drugs. 2017 Aug;35(4):499-508 - PubMed
  5. Virchows Arch. 2007 Aug;451 Suppl 1:S29-38 - PubMed
  6. Lancet Diabetes Endocrinol. 2015 Nov;3(11):895-905 - PubMed
  7. J Clin Oncol. 1999 Apr;17(4):1111 - PubMed
  8. J Endocrinol Invest. 2012 Mar;35(3):326-31 - PubMed
  9. Curr Treat Options Oncol. 2020 Apr 30;21(6):50 - PubMed
  10. J Clin Endocrinol Metab. 2020 Jan 1;105(1): - PubMed
  11. Nature. 1988 Mar 3;332(6159):85-7 - PubMed
  12. Clin J Gastroenterol. 2021 Feb;14(1):358-363 - PubMed
  13. Ann Oncol. 2001;12 Suppl 2:S105-9 - PubMed
  14. Case Rep Gastrointest Med. 2019 Apr 30;2019:9462942 - PubMed
  15. Neuroendocrinology. 2016;103(2):153-71 - PubMed
  16. Ann Oncol. 2000 Sep;11(9):1127-30 - PubMed
  17. Am J Gastroenterol. 2000 Nov;95(11):3276-81 - PubMed
  18. J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011 - PubMed
  19. J Cancer Res Ther. 2014 Apr-Jun;10(2):443-5 - PubMed
  20. Fam Cancer. 2011 Mar;10(1):157-71 - PubMed
  21. Nat Rev Endocrinol. 2021 Apr;17(4):207-224 - PubMed
  22. J Clin Endocrinol Metab. 2015 Apr;100(4):1568-77 - PubMed
  23. Cancer. 1999 Nov 15;86(10):2154-9 - PubMed
  24. Cancer. 2002 Jan 15;94(2):331-43 - PubMed
  25. Horm Metab Res. 2011 Oct;43(11):794-800 - PubMed
  26. J Endocrinol Invest. 2012 Oct;35(9):817-23 - PubMed
  27. Ann Oncol. 2006 Mar;17(3):461-6 - PubMed
  28. Endocr Pract. 2011 Jan-Feb;17(1):79-84 - PubMed
  29. Invest New Drugs. 2019 Aug;37(4):763-770 - PubMed
  30. J Surg Case Rep. 2017 Dec 11;2017(12):rjx244 - PubMed
  31. N Engl J Med. 2014 Oct 16;371(16):1556-7 - PubMed
  32. Neuroendocrinology. 2016;103(2):172-85 - PubMed
  33. Eur J Gastroenterol Hepatol. 2013 Jul;25(7):858-62 - PubMed
  34. Clin Endocrinol (Oxf). 2015 Nov;83(5):618-21 - PubMed
  35. N Engl J Med. 2000 Aug 24;343(8):551-4 - PubMed
  36. Endocr Rev. 2021 Mar 15;42(2):133-170 - PubMed
  37. F1000Res. 2017 Jan 24;6: - PubMed
  38. Front Neuroendocrinol. 2013 Aug;34(3):228-52 - PubMed
  39. Endocr Relat Cancer. 2016 Mar;23(3):191-9 - PubMed
  40. Endocrinol Metab Clin North Am. 2018 Sep;47(3):549-555 - PubMed
  41. World J Surg. 2010 Feb;34(2):249-55 - PubMed
  42. Int J Mol Sci. 2020 Feb 29;21(5): - PubMed
  43. N Engl J Med. 2017 Jan 12;376(2):125-135 - PubMed
  44. Gastroenterology. 2010 Sep;139(3):742-53, 753.e1 - PubMed
  45. Pathobiology. 2007;74(5):279-84 - PubMed
  46. Neuroendocrinology. 2021;111(7):650-659 - PubMed
  47. Clin Endocrinol (Oxf). 2014 Jun;80(6):850-5 - PubMed
  48. Endocrine. 2020 Apr;68(1):222-229 - PubMed
  49. Ann Oncol. 2004 Jun;15(6):966-73 - PubMed
  50. World J Surg Oncol. 2019 Dec 9;17(1):213 - PubMed
  51. J Mol Endocrinol. 2018 Jul;61(1):R13-R24 - PubMed
  52. Pancreas. 2016 Nov;45(10):1386-1393 - PubMed
  53. Transl Gastroenterol Hepatol. 2016 Nov 30;1:88 - PubMed
  54. Intern Med. 2010;49(15):1557-63 - PubMed
  55. J Clin Endocrinol Metab. 2003 Nov;88(11):5353-60 - PubMed
  56. Cancer. 2013 Dec 1;119(23):4094-102 - PubMed
  57. Oncotarget. 2016 Feb 2;7(5):5538-47 - PubMed
  58. Front Horm Res. 2013;41:1-15 - PubMed
  59. J Clin Oncol. 2009 Oct 1;27(28):4656-63 - PubMed
  60. J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 - PubMed
  61. J Clin Endocrinol Metab. 2020 Jan 1;105(1): - PubMed
  62. Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):123-130 - PubMed

Publication Types

Grant support